Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. ACN
6. NVDA
7. IBM
8. PRIM
9. SPY
10. DPZ

Go back to Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
(NASDAQ: PVLA) Delayed: 118.12 -0.72 (0.61%)
Previous Close $118.84    52 Week High $ 
Open $116.83    52 Week Low $ 
Day High $120.63    P/E N/A 
Day Low $116.83    EPS $ 
Volume 112,790